KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibitsantidiabetic efficacy in rodent models

Journal of Pharmacology and Experimental Therapeutics

Volumn 342, Issue 2, 2012, Pages 288-296

  Shibazaki, Toshihide ^a   Tomae, Masaki ^a   Ishikawa Takemura, Yukiko ^a   Fushimi, Nobuhiko ^a   Itoh, Fumiaki ^a   Yamada, Mitsuhiko ^b   Isaji, Masayuki ^a  

^a KISSEI PHARMACEUTICAL CO LTD   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 [4 [3 (BETA DEXTRO GLUCOPYRANOSYLOXY) 5 ISOPROPYL 1HPYRAZOL 4 YL] 3 METHYPHENOXY]PROYLAMINO]PROPIONAMIDE; ACARBOSE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; KGA 2727; PHLORIZIN; PROTEIN INHIBITOR; SODIUM GLUCOSE COTRANSPORTER 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HYPERGLYCEMIA; INSULIN RELEASE; KIDNEY DISTAL TUBULE; MALE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RAT; STREPTOZOCIN DIABETES; TREATMENT OUTCOME; UPREGULATION;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INTESTINAL ABSORPTION; INTESTINE, SMALL; ISLETS OF LANGERHANS; MALE; PYRAZOLES; RATS; RATS, WISTAR; RATS, ZUCKER; SODIUM-GLUCOSE TRANSPORTER 1;

EID: 84864118760     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.193045     Document Type: Article

References (41)

1. Baggio LL and Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131-2157. (Pubitemid 46711096)
2. Bray GA, Nielsen SJ, and Popkin BM (2004) Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. Am J Clin Nutr 79:537-543.
3. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, and STOPNIDDM Trail Research Group (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072-2077. (Pubitemid 34680970)
4. Coimbra TM, Janssen U, Gröne HJ, Ostendorf T, Kunter U, Schmidt H, Brabant G, and Floege J (2000) Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 57:167-182. (Pubitemid 30227764)
5. DECODE Study Group and the European Diabetes Epidemiology Group. (2001) Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161:397-405.
6. Dyer J, Garner A, Wood IS, Sharma AK, Chandranath I, and Shirazi-Beechey SP (1997) Changes in the levels of intestinal Na/glucose co-transporter (SGLT1) in experimental diabetes. Biochem Soc Trans 25:479S.
7. Dyer J, Wood IS, Palejwala A, Ellis A, and Shirazi-Beechey SP (2002) Expression of monosaccharide transporters in intestine of diabetic humans. Am J Physiol Gastrointest Liver Physiol 282:G241-G248. (Pubitemid 34651680)
8. Ehrenkranz JR, Lewis NG, Kahn CR, and Roth J (2005) Phlorizin: a review. Diabetes Metab Res Rev 21:31-38.
9. Eizirik DL, Cardozo AK, and Cnop M (2008) The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev 29:42-61. (Pubitemid 351252746)
10. Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, and Isaji M (2008) Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 327:268-276.
11. Fujimori Y, Katsuno K, Ojima K, Nakashima I, Nakano S, Ishikawa-Takemura Y, Kusama H, and Isaji M (2009) Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol 609:148-154.
12. Fujita Y, Kojima H, Hidaka H, Fujimiya M, Kashiwagi A, and Kikkawa R (1998) Increased intestinal glucose absorption and postprandial hyperglycaemia at the early step of glucose intolerance in Otsuka Long-Evans Tokushima Fatty rats. Diabetologia 41:1459-1466. (Pubitemid 28551617)
13. Fukaya N, Mochizuki K, Tanaka Y, Kumazawa T, Jiuxin Z, Fuchigami M, and Goda T (2009) The α-glucosidase inhibitor miglitol delays the development of diabetes and dysfunctional insulin secretion in pancreatic β-cells in OLETF rats. Eur J Pharmacol 624:51-57.
14. Goda T, Suruga K, Komori A, Kuranuki S, Mochizuki K, Makita Y, and Kumazawa T (2007) Effects of miglitol, an α-glucosidase inhibitor, on glycaemic status and histopathological changes in islets in non-obese, non-insulin-dependent diabetic Goto-Kakizaki rats. Br J Nutr 98:702-710. (Pubitemid 47489731)
15. Göke B and Herrmann-Rinke C (1998) The evolving role of α-glucosidase inhibitors. Diabetes Metab Rev 14:S31-S38.
16. Gorboulev V, Schürmann A, Vallon V, Kipp H, Jaschke A, Klessen D, Friedrich A, Scherneck S, Rieg T, Cunard R, et al. (2012) Na-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61:187-196.
17. International Diabetes Federation (2011) 2011 Guideline for Management of Post-meal Glucose in Diabetes. International Diabetes Federation, Brussels, Belgium.
18. Isaji M (2011) SGLT2 inhibitors: molecular design and potential differences in effect. Kidney Int Suppl 120:S14-S19.
19. Katsuno K, Fujimori Y, Ishikawa-Takemura Y, and Isaji M (2009) Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KKA(y) mice. Eur J Pharmacol 618:98-104.
20. Katsuno K, Fujimori Y, Takemura Y, Hiratochi M, Itoh F, Komatsu Y, Fujikura H, and Isaji M (2007) Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 320:323-330. (Pubitemid 46025747)
21. Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K, and Voglibose Ph-3 Study Group (2009) Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 373:1607-1614.
22. Kinne RK and Castaneda F (2011) SGLT inhibitors as new therapeutic tools in the treatment of diabetes. Handb Exp Pharmacol 203:105-126.
23. Koyama M, Wada R, Mizukami H, Sakuraba H, Odaka H, Ikeda H, and Yagihashi S (2000) Inhibition of progressive reduction of islet β-cell mass in spontaneously diabetic Goto-Kakizaki rats by α-glucosidase inhibitor. Metabolism 49:347-352. (Pubitemid 30146566)
24. Levin RJ (1994) Digestion and absorption of carbohydrates-from molecules and membranes to humans. Am J Clin Nutr 59:690S-698S.
25. Malik VS, Popkin BM, Bray GA, Després JP, Willett WC, and Hu FB (2010) Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: a meta-analysis. Diabetes Care 33:2477-2483.
26. Meng W, Ellsworth BA, Nirschl AA, McCann PJ, Patel M, Girotra RN, Wu G, Sher PM, Morrison EP, Biller SA, et al. (2008) Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 51:1145-1149. (Pubitemid 351480378)
27. Moritoh Y, Takeuchi K, and Hazama M (2009) Chronic administration of voglibose, an α-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice. J Pharmacol Exp Ther 329:669-676.
28. +-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 48:1794-1800.
29. Prentki M and Nolan CJ (2006) Islet β cell failure in type 2 diabetes. J Clin Invest 116:1802-1812. (Pubitemid 44033300)
30. Qualmann C, Nauck MA, Holst JJ, Orskov C, and Creutzfeldt W (1995) Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using α-glucosidase inhibition (acarbose). Scand J Gastroenterol 30:892-896.
31. Robertson RP, Harmon J, Tran PO, Tanaka Y, and Takahashi H (2003) Glucose toxicity in β-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 52:581-587. (Pubitemid 36323562)
32. Rossetti L, Shulman GI, Zawalich W, and DeFronzo RA (1987) Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 80:1037-1044. (Pubitemid 18075639)
33. Shiraiwa T, Kaneto H, Miyatsuka T, Kato K, Yamamoto K, Kawashima A, Kanda T, Suzuki M, Imano E, Matsuhisa M, et al. (2005) Post-prandial hyperglycemia is an important predictor of the incidence of diabetic microangiopathy in Japanese type 2 diabetic patients. Biochem Biophys Res Commun 336:339-345. (Pubitemid 41253439)
34. Sugimoto K, Rashid IB, Kojima K, Shoji M, Tanabe J, Tamasawa N, Suda T, and Yasujima M (2008) Time course of pain sensation in rat models of insulin resistance, type 2 diabetes, and exogenous hyperinsulinaemia. Diabetes Metab Res Rev 24:642-650.
35. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986.
36. +/glucose cotransporter. Nature 350:354-356.
37. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853.
38. Williams SB, Goldfine AB, Timimi FK, Ting HH, Roddy MA, Simonson DC, and Creager MA (1998) Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 97:1695-1701. (Pubitemid 28211418)
39. Woerle HJ, Neumann C, Zschau S, Tenner S, Irsigler A, Schirra J, Gerich JE, and Göke B (2007) Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract 77:280-285. (Pubitemid 46670411)
40. Wright EM, Hirayama BA, and Loo DF (2007) Active sugar transport in health and disease. J Intern Med 261:32-43. (Pubitemid 46046470)
41. Yamagishi S, Fukami K, Ueda S, and Okuda S (2007) Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr Drug Targets 8:952-959.